Novo Nordisk has severed ties with Hims & Hers Health, Inc. after just one month, citing the telehealth company's continued sale of 'illegitimate, knockoff' compounded semaglutide products. The pharmaceutical giant alleges that Hims & Hers engaged in deceptive marketing and illegal mass compounding, which puts patients at risk by using unregulated, potentially foreign-sourced ingredients. This move follows the FDA's recent resolution of the Wegovy shortage, allowing Novo Nordisk to strictly enforce the use of its FDA-approved medication over unauthorized alternatives.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.